Systemic therapy with immune checkpoint inhibitors or combined BRAF/MEK-targeted therapy is recommended by international guidelines for patients with resected stage IIB to IV melanoma, as well as for those with unresectable or metastatic disease (65, 66). Here, MAP2K7 is linked to metastatic neoplasm.